Drug pricing negotiations stories

Medicare policy change grants AbbVie's Creon seven additional years before price negotiations, advocacy group claims

Public Citizen alleges that a little-noticed Medicare rule change will exempt AbbVie's pancreatic insufficiency drug Creon from price negotiations for seven extra years, potentially costing taxpayers billions. The controversy emerges amid broader debates over Medicare drug pricing policies and their fiscal impact.